EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rationale for the milvexian dosing in the phase 3 LIBREXIA program

Jeffrey I Weitz, Robert A Harrington, LIBREXIA Program Executive Council

Journal of Thrombosis and Haemostasis · 2026-06 · 24 (6) · 2158-2169

DOI: 10.1016/j.jtha.2026.02.020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-06. Verfasst von Jeffrey I Weitz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Rese…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Acute Coronary Syndrome, Stroke, Anticoagulants. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Johnson & Johnson Pharmaceutical Research and Development LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Milvexian is an oral, small-molecule inhibitor of factor (F)XIa undergoing evaluation in phase 3 clinical trials. OBJECTIVES: This manuscript aimed to explain the rationale underpinning the hypothesis that FXIa may be a safer target for anticoagulants than FXa; describe the pharmacology of milvexian; review the results of the phase 2 trials with milvexian; and detail how the phase 2 program informed the dosing regimens for the phase 3 trials. METHODS: This narrative review addresses the above objectives with the primary focus on addressing how the milvexian dosing regimens were selected for the phase 3 LIBREXIA program, which compares milvexian with apixaban for atrial fibrillation (AF) in the LIBREXIA AF trial (NCT05757869) and with placebo, in addition to background single or dual antiplatelet therapy, in patients with acute coronary syndrome (ACS) in the LIBREXIA ACS trial (NCT05754957), and for noncardioembolic ischemic stroke and high-risk transient ischemic attack in the LIBREXIA Stroke trial (NCT05702034). RESULTS: The milvexian dose regimen selected for the LIBREXIA AF trial is 100 mg twice daily, and for the LIBREXIA ACS and Stroke trials, it is 25 mg twice daily. CONCLUSIONS: The phase 3 LIBREXIA program will determine whether these dose regimens afford safe and effective anticoagulation in approximately 50 000 patients with AF, ACS, or prior stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAcute Coronary SyndromeStrokeAnticoagulantsPyrazolesHumansClinical Trials, Phase III as TopicTreatment OutcomeIschemic Attack, TransientPyridonesAdministration, OralHemorrhagePyrimidinesTriazoles

Stichwörter der Autor:innen

acute coronary syndromeatrial fibrillationfactor XImilvexianstroke

Substanzen

AnticoagulantsPyrazolesPyridonesapixabanmilvexianPyrimidinesTriazoles

Autor:innen und Institutionen

  • Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Hamilton Health Sciences, H…
  • Weill Cornell Medicine, Cornell University, New York, New York, USA.

Förderung

  • Bristol-Myers Squibb
  • Johnson & Johnson Pharmaceutical Research and Development LLC

Zitieren

APA

Weitz, J. I., Harrington, R. A., & LIBREXIA Program Executive Council (2026). Rationale for the milvexian dosing in the phase 3 LIBREXIA program. Journal of Thrombosis and Haemostasis, 24(6), 2158-2169. https://doi.org/10.1016/j.jtha.2026.02.020

Vancouver

Weitz JI, Harrington RA, LIBREXIA Program Executive Council. Rationale for the milvexian dosing in the phase 3 LIBREXIA program. Journal of Thrombosis and Haemostasis. 2026;24(6):2158-2169. doi:10.1016/j.jtha.2026.02.020

BibTeX
@article{Weitz2026,
  author = {Weitz, Jeffrey I and Harrington, Robert A and LIBREXIA Program Executive Council, LIBREXIA Program Executive Council},
  title = {Rationale for the milvexian dosing in the phase 3 LIBREXIA program},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {6},
  pages = {2158--2169},
  doi = {10.1016/j.jtha.2026.02.020}
}
Kostenlos starten →